# Edward Keystone

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/edward-keystone/

## Facts

| Field | Value |
| --- | --- |
| Citations | 37,661 |
| Field | Rheumatoid Arthritis Research and Therapies |
| h-index | 85 |
| i10-index | 280 |
| Last Known Institution | University of Toronto |
| OpenAlex ID | https://openalex.org/A5080646462 |
| ORCID iD | https://orcid.org/0000-0001-6606-0071 |
| Works | 571 |

## Researcher papers

- [Treating rheumatoid arthritis to target: recommendations of an international task force](https://scholariq.org/papers/treating-rheumatoid-arthritis-to-target-recommendations-of-an-international-task/)
- [Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks](https://scholariq.org/papers/rituximab-for-rheumatoid-arthritis-refractory-to-anti-tumor-necrosis-factor/)
- [IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial](https://scholariq.org/papers/il-6-receptor-inhibition-with-tocilizumab-improves-treatment-outcomes-in/)
- [American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials](https://scholariq.org/papers/american-college-of-rheumatology-european-league-against-rheumatism-provisional/)
- [Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis](https://scholariq.org/papers/baricitinib-versus-placebo-or-adalimumab-in-rheumatoid-arthritis/)
- [Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)](https://scholariq.org/papers/sustained-benefits-of-infliximab-therapy-for-dermatologic-and-articular/)
- [Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study](https://scholariq.org/papers/tofacitinib-cp-690-550-in-patients-with-rheumatoid-arthritis-receiving/)

## Researcher topics

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Autoimmune and Inflammatory Disorders Research](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders-research/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)

## Researcher university

- [University of Toronto](https://scholariq.org/institutions/university-of-toronto/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.